fbpx Skip to main content

Member's Profile


2250 W Whittier Blvd Ste 300
La Habra,   California
United States
Membership Info
Membership Type: Industry
Membership Since: 2021
Need to make an update to your Member Profile or have a question? Contact us here: [email protected]
About Oculogenex
Biotech Company
Oculogenex is developing a disruptive gene therapy technology that will have a global impact by offering a treatment to avoid irreversible vision loss from advanced dry macular degeneration, glaucoma, and diabetic retinopathy. Our ocular gene therapy epigenetically reprograms damaged cells to repair DNA damage, boost antioxidants, and resist cell death. While ocular gene therapy is FDA-approved for gene replacement, our approach is original because it reprograms injured cells to heal and regenerate and can be used for patients with any genetic background. When commercialized, our technology will be transformative because it will provide a solution for the leading causes of blindness with a safe, durable, and cost-effective therapy. The global cost of vision loss due to all causes is estimated to be nearly $3 trillion dollars annually for the 733 million people living with low vision and blindness worldwide.
Related News
No related news posted by this Member